5,450.49

Content Details
Information on this page was last modified on : 2023/12/30 11:33:48 PM

Minirin tablet 0.1 mg 30’s

Minirin tablet contains Desmopressin | belongs to Vasopressin analogue

Alternate brands of Minirin tablet 0.1 mg 30’s

Brand Name Price Savings
Minirin Injection 4 mcg/mL 10 Amp  4,466.00 You can save 984.49
Minirin tablet 0.2 mg 30’s  8,849.64 You will pay -3399.15 more
Minirin Nasal Spray Aq 0.01 mg/Dose 2.5 mL  4,415.74 You can save 1034.75
List of alternate brands

How it works

Minirin tablet 0.1 mg 30’s works by replacing vasopressin, a hormone that is normally produced in the body to help balance the amount of water and salt.

Uses of Minirin tablet 0.1 mg 30’s

What is it prescribed for?

  • Diabetes insipidus

    This medicine is used in the treatment of diabetes insipidus, a condition characterized by symptoms such as increased thirst and increased amount of urination.

  • Hemophilia A

    The injectable and intranasal forms of this medicine are used to maintain hemostasis in patients suffering from Hemophilia A, a genetic deficiency of a clotting factor, which results in an increased amount of bleeding.

  • Von Willebrand Disease

    The injectable and intranasal forms of this medicine are used to maintain hemostasis in patients suffering from Von Willebrand Disease, which is a genetic disorder caused by missing or defective von Willebrand factor (VWF), that may result in an excessive amount of bleeding.

  • Bedwetting

    The oral form of this medicine is used in the treatment of bedwetting (primary nocturnal enuresis).

Concerns

Frequently asked questions

  • Onset of action

    The effect of this medicine can be observed within 30 minutes of intravenous administration and within 60 minutes of intranasal or oral administration.

  • Duration of Effect

    The effect of this medicine lasts for an average duration of 6 to 14 hours.

  • Safe with Alchohol?

    Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.

  • Is it habit forming?

    No habit-forming tendencies were reported.

  • Usage in pregnancy?

    This medicine is not recommended for use in pregnant women unless necessary. All the risks and benefits should be discussed with the doctor before taking/receiving this medicine.

  • Usage while breast-feeding?

    This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before taking/receiving this medicine.

When not to use?

  • Allergy

    This medicine is not recommended for use in patients with a known allergy to Minirin tablet 0.1 mg 30’s or any other inactive ingredients present along with it.

  • Renal impairment

    This medicine is not recommended for use in patients suffering from a moderate-to-severe renal impairment (CrCl less than 50 ml/min) due to the increased risk of worsening of the patient's condition.

  • Hyponatremia

    This medicine is not recommended for use in patients suffering from hyponatremia (decreased sodium levels) or patients with a history of hyponatremia due to the increased risk of worsening of the patient's condition.

Warnings

Warnings for special population
  • Pregnancy

    This medicine is not recommended for use in pregnant women unless necessary. All the risks and benefits should be discussed with the doctor before taking/receiving this medicine.Breast-feeding

  • Breast-feeding

    This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before taking/receiving this medicine.

General Warnings
  • Fluid restriction

    This medicine may lead to water intoxication and/or very low blood sodium levels which may be fatal in some patients. Hence, fluid restriction is recommended during treatment with this medicine, especially when the medicine is not used to control increased urination. Report any symptoms such as a headache, nausea, vomiting, weight gain, restlessness, fatigue, lethargy, disorientation, depressed reflexes, loss of appetite, irritability, muscle weakness, muscle spasms or cramps, hallucinations, decreased levels of consciousness, confusion, etc. to the doctor immediately. Close monitoring of blood sodium levels, appropriate patient/caregiver counseling, dose adjustments, or replacement with a suitable alternative may be necessary based on the clinical condition of the patient.

  • Type IIB von Willebrand’s disease

    This medicine is not recommended for use in patients suffering from type IIB Von Willebrand disease due to the increased risk of worsening of the patient's condition. Appropriate diagnostic tests should be done to determine the type of Von Willebrand disease prior to beginning therapy with this medicine. Replacement with a suitable alternative may be necessary based on the clinical condition of the patient.

  • Habitual polydipsia (increased thirst)

    This medicine should be used with caution in patients with habitual or psychogenic polydipsia who may be more likely to drink excessive amounts of water, due to the increased risk of water intoxication and decreased blood sodium levels. Close monitoring of blood sodium levels, appropriate patient/caregiver counseling, dose adjustments, or replacement with a suitable alternative may be necessary based on the clinical condition of the patient.

Dosage

  • Missed Dose

    Nasal and oral forms: If a dose is missed, take/administer it as soon as you remember. If it is almost time for the next dose, skip the missed dose and take/administer the next dose. Do not double the dose to make up for the missed one. Injectable forms: Since this medicine is usually administered in the hospital/clinical setting by a qualified healthcare professional, the likelihood of missing a dose is very low.

  • Overdose

    Nasal and oral forms: Seek emergency medical treatment or contact the doctor in case of an overdose. Injectable forms: Since this medicine is usually administered in the hospital/clinical setting by a qualified healthcare professional, the likelihood of an overdose is very low. However, emergency medical treatment will be initiated by your doctor if an overdose is suspected.

Interactions

Interaction with Medicines
  • NSAIDs moderate
  • Tricyclic Antidepressants moderate
  • SSRIs moderate

General Instructions

Nasal/Oral forms: Use this medicine exactly as advised by your doctor. Do not use in larger or smaller amounts than advised/prescribed. Consult the doctor if you experience any undesirable side effects. Ensure that the treatment course is completed. Do not stop the use of this medicine without consulting your doctor. Injectable forms: This medicine is generally used prior to a surgical procedure to reduce bleeding in patients suffering from hemophilia A and/or von Willebrand disease. Inform the doctor if you have a known history of an allergy to this medicine. Report to the doctor all your current medications including any herbs and supplements as well as your medical history before undergoing treatment with this medicine.

References

Additional Information:

How to use Minirin tablet 0.1 mg 30’s

IV: Dilute in 0.9% NaCl and infuse over 15-30 min; dose should be diluted in 10 mL NS for children lt; 10 kg; 50 mL NS for adults and children gt; 10 kg.
Stability: Store under refrigeration at 2°C-8°C (36°F-46°F).

UNLICENSED USE
Children: Assessment of antidiuretic hormone secretion when congenital deficiency suspected: Intranasally. 1 mth-2 yr, initially 100-500 nanograms as a single dose. Assessment of antidiuretic hormone secretion when congenital deficiency not suspected: Intranasally. 1 mth-2 yr, 1-5 micrograms as a single dose.

what are the adverse effects of Minirin tablet 0.1 mg 30’s?

Overhydration, hyponatraemia, headache, nausea.

What happens if I miss a dose of Minirin tablet 0.1 mg 30’s?

Adults: TAB/SPRAY: Diabetes insipidus, treatment: TAB: Initially 300 mcg/day as t.i.d; maintenance, 300-600 mcg/day as t.i.d; range 0.2-1.2 mg/day. SPRAY: 10-40 mcg/day as od/bid doses.
Diabetes insipidus, diagnosis: SPRAY: 20 mcg (limit fluid intake to 500 mL from 1 hr before to 8 hrs after administration); Adults above 65 yrs, 10-20 mcg at bed time, do not repeat dose within 24 hrs.
Primary nocturnal enuresis (if urine concentrating ability normal). Nocturia associated with multiple sclerosis (when other treatments have failed): TAB: 200 mcg at bed time, only increased to 400 mcg if lower dose not effective; withdraw for at least 1 wk for reassessment after 3 mth. SPRAY: Adults above 65 yrs, 10-20 mcg at bed time, do not repeat dose within 24 hrs. Postoperative polyuria or polydipsia: Adjust dose according to urine osmolarity.
Renal function testing: (Empty bladder at time of dose and limit fluid intake to 500 mL from 1 hr before until 8 hrs after dose): SPRAY: 40 mcg.
Adults: INJECTION: SC/IM: Diabetes insipidus, diagnosis: 2 mcg (limit fluid intake to 500 mL from 1 hr before to 8 hrs of dose).
Diabetes insipidus, treatment: 1-4 mcg/day.
Renal function testing: Empty bladder at time of dose and limit fluid intake to 500 mL from 1 hr before until 8 hrs of dose. 2 mcg.
Children: Test for suspected diabetes insipidus (water deprivation test): Intranasally: Neonate, not recommended, 1 mth-2 yrs, 5-10 mcg as a single dose; not usually recommended; 2-12 yrs, 10-20 mcg as a single dose; 12-18 yrs, 20 mcg as a single dose. SC or IM injection: Neonate, not recommended; 1 mth-2 yrs, 400 nanograms as a single dose; not usually recommended; 2-12 yrs, 0.5-1 mcg as a single dose; 12-18 yrs, 1-2 mcg as a single dose. Diabetes insipidus, treatment (The dosage adjusted according to response): Oral (as desmopressin acetate): Neonate, initially 1-4 mcg 2-3 times daily; 1 mth-2 yr, initially 10 mcg 2-3 times daily (range 30-150 mcg daily); 2-12 yr, initially 50 mcg 2-3 times daily (range 100-800 mcg daily); 12-18 yr, initially 100 mcg 2-3 times daily (range 0.2-1.2 mg daily). Sublingually (as desmopressin base): 2-18 yr, initially 60 mcg 3 times daily (range 40-240 mcg 3 times daily). Intranasally (as desmopressin acetate): Neonate, initially 100-500 nanograms (range 1.25-10 mcg daily in 1-2 divided doses); 1 mth-2 yr, initially 2.5-5 mcg 1-2 times daily; 2-12 yr, initially 5-20 mcg 1-2 times daily; 12-18 yr, initially 10-20 mcg 1-2 times daily. SC or IM injection: Neonate, initially 100 nanograms once daily, adjusted according to response (intramuscular route only); 1 mth-12 yr, initially 400 nanograms once daily; 12-18 yr, initially 1-4 mcg once daily.
Primary nocturnal enuresis: Oral (as desmopressin acetate): 5-18 yr, 200 mcg at bedtime, increased to 400 mcg at bedtime only if lower dose not effective, reassess after 3 mth by withdrawing treatment for at least 1 wk. Sublingually (as desmopressin base): 5-18 yr, 120 mcg at bedtime, increased to 240 mcg at bedtime only if lower dose not effective; reassess after 3 mth by withdrawing treatment for at least 1 wk.
Fibrinolytic response testing: IV injection over 20 minutes or SC injection: 2-18 yr, 300 nanograms/kg as a single dose; blood sampled after 20 minutes for fibrinolytic activity.

One of the following licensed pharmacy from the nearest location will deliver Minirin tablet 0.1 mg 30’s. The details of the licensed pharmacy shall be shared once you request the drugs and the respective pharmacy accepts your request based on valid prescription and availability.

Want to share this information?
Facebook
Twitter
LinkedIn
Something doesn't feel right ?

Questions and Answers

There are no questions yet. Be the first to ask a question about this product.

Only registered users are eligible to enter questions

1 review for Minirin tablet 0.1 mg 30’s

  1. Atif Wattoo

    please deliver early

Add a review
Shopping Cart